CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 907 enrolled
Drug / intervention
Comparator: montelukast/loratadine +3 moredrug
Likely dose
Comparator: montelukast/loratadine 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00963599
NCT00963599Phase 3Completed
CompareCT.gov

A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Combination Montelukast/Loratadine in Patients With Seasonal Allergic Rhinitis-Fall Study

Organon and Co·interventional·Posted Aug 21, 2009·Updated Feb 9, 2022

In Brief

A Phase 3 clinical trial evaluating Comparator: montelukast/loratadine, Comparator: montelukast, and 2 other interventions for Seasonal Allergic Rhinitis. Completed, enrolled 907 participants.

Detailed Summary

This study will evaluate the ability of oral montelukast/loratadine to improve the signs and symptoms of seasonal allergic rhinitis compared with loratadine alone, montelukast alone and placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 21, 2009
Enrollment StartSep 1, 1999
Primary CompletionNov 1, 1999
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 16.9 years ago

Interventions

Comparator: montelukast/loratadinedrug

montelukast 10 mg/loratadine 10 mg tablet taken once daily at bed time for 2 weeks

Comparator: montelukastdrug

montelukast 10 mg tablet taken once daily at bed time for 2 weeks

Comparator: loratadinedrug

loratadine 10 mg tablet taken once daily at bed time for 2 weeks

Comparator: placebodrug

placebo tablet taken once daily at bed time for 2 weeks